Cargando…

Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review

BACKGROUND: Continuing progress in the global pediatric human immunodeficiency virus (HIV) response depends on timely identification and care of infants with HIV. As countries scale-out improvements to HIV early infant diagnosis (EID), economic evaluations are needed to inform program design and imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsbernd, Kira, Emmert-Fees, Karl M. F., Erbe, Amanda, Ottobrino, Veronica, Kroidl, Arne, Bärnighausen, Till, Geisler, Benjamin P., Kohler, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284833/
https://www.ncbi.nlm.nih.gov/pubmed/35841117
http://dx.doi.org/10.1186/s40249-022-01006-7
_version_ 1784747650794389504
author Elsbernd, Kira
Emmert-Fees, Karl M. F.
Erbe, Amanda
Ottobrino, Veronica
Kroidl, Arne
Bärnighausen, Till
Geisler, Benjamin P.
Kohler, Stefan
author_facet Elsbernd, Kira
Emmert-Fees, Karl M. F.
Erbe, Amanda
Ottobrino, Veronica
Kroidl, Arne
Bärnighausen, Till
Geisler, Benjamin P.
Kohler, Stefan
author_sort Elsbernd, Kira
collection PubMed
description BACKGROUND: Continuing progress in the global pediatric human immunodeficiency virus (HIV) response depends on timely identification and care of infants with HIV. As countries scale-out improvements to HIV early infant diagnosis (EID), economic evaluations are needed to inform program design and implementation. This scoping review aimed to summarize the available evidence and discuss practical implications of cost and cost-effectiveness analyses of HIV EID. METHODS: We systematically searched bibliographic databases (Embase, MEDLINE and EconLit) and grey literature for economic analyses of HIV EID in low- and middle-income countries published between January 2008 and June 2021. We extracted data on unit costs, cost savings, and incremental cost-effectiveness ratios as well as outcomes related to health and the HIV EID care process and summarized results in narrative and tabular formats. We converted unit costs to 2021 USD for easier comparison of costs across studies. RESULTS: After title and abstract screening of 1278 records and full-text review of 99 records, we included 29 studies: 17 cost analyses and 12 model-based cost-effectiveness analyses. Unit costs were 21.46–51.80 USD for point-of-care EID tests and 16.21–42.73 USD for laboratory-based EID tests. All cost-effectiveness analyses stated at least one of the interventions evaluated to be cost-effective. Most studies reported costs of EID testing strategies; however, few studies assessed the same intervention or reported costs in the same way, making comparison of costs across studies challenging. Limited data availability of context-appropriate costs and outcomes of children with HIV as well as structural heterogeneity of cost-effectiveness modelling studies limits generalizability of economic analyses of HIV EID. CONCLUSIONS: The available cost and cost-effectiveness evidence for EID of HIV, while not directly comparable across studies, covers a broad range of interventions and suggests most interventions designed to improve EID are cost-effective or cost-saving. Further studies capturing costs and benefits of EID services as they are delivered in real-world settings are needed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40249-022-01006-7.
format Online
Article
Text
id pubmed-9284833
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92848332022-07-16 Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review Elsbernd, Kira Emmert-Fees, Karl M. F. Erbe, Amanda Ottobrino, Veronica Kroidl, Arne Bärnighausen, Till Geisler, Benjamin P. Kohler, Stefan Infect Dis Poverty Scoping Review BACKGROUND: Continuing progress in the global pediatric human immunodeficiency virus (HIV) response depends on timely identification and care of infants with HIV. As countries scale-out improvements to HIV early infant diagnosis (EID), economic evaluations are needed to inform program design and implementation. This scoping review aimed to summarize the available evidence and discuss practical implications of cost and cost-effectiveness analyses of HIV EID. METHODS: We systematically searched bibliographic databases (Embase, MEDLINE and EconLit) and grey literature for economic analyses of HIV EID in low- and middle-income countries published between January 2008 and June 2021. We extracted data on unit costs, cost savings, and incremental cost-effectiveness ratios as well as outcomes related to health and the HIV EID care process and summarized results in narrative and tabular formats. We converted unit costs to 2021 USD for easier comparison of costs across studies. RESULTS: After title and abstract screening of 1278 records and full-text review of 99 records, we included 29 studies: 17 cost analyses and 12 model-based cost-effectiveness analyses. Unit costs were 21.46–51.80 USD for point-of-care EID tests and 16.21–42.73 USD for laboratory-based EID tests. All cost-effectiveness analyses stated at least one of the interventions evaluated to be cost-effective. Most studies reported costs of EID testing strategies; however, few studies assessed the same intervention or reported costs in the same way, making comparison of costs across studies challenging. Limited data availability of context-appropriate costs and outcomes of children with HIV as well as structural heterogeneity of cost-effectiveness modelling studies limits generalizability of economic analyses of HIV EID. CONCLUSIONS: The available cost and cost-effectiveness evidence for EID of HIV, while not directly comparable across studies, covers a broad range of interventions and suggests most interventions designed to improve EID are cost-effective or cost-saving. Further studies capturing costs and benefits of EID services as they are delivered in real-world settings are needed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40249-022-01006-7. BioMed Central 2022-07-15 /pmc/articles/PMC9284833/ /pubmed/35841117 http://dx.doi.org/10.1186/s40249-022-01006-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Scoping Review
Elsbernd, Kira
Emmert-Fees, Karl M. F.
Erbe, Amanda
Ottobrino, Veronica
Kroidl, Arne
Bärnighausen, Till
Geisler, Benjamin P.
Kohler, Stefan
Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title_full Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title_fullStr Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title_full_unstemmed Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title_short Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review
title_sort costs and cost-effectiveness of hiv early infant diagnosis in low- and middle-income countries: a scoping review
topic Scoping Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284833/
https://www.ncbi.nlm.nih.gov/pubmed/35841117
http://dx.doi.org/10.1186/s40249-022-01006-7
work_keys_str_mv AT elsberndkira costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT emmertfeeskarlmf costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT erbeamanda costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT ottobrinoveronica costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT kroidlarne costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT barnighausentill costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT geislerbenjaminp costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview
AT kohlerstefan costsandcosteffectivenessofhivearlyinfantdiagnosisinlowandmiddleincomecountriesascopingreview